Drug class in one race
KRAS Mutant drugs for Non-Small Cell Lung Cancer
3 tracked KRAS Mutant drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the KRAS Mutant page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 Phase 11 preclinical / unstaged